Flexion CEO Makes The Case For Zilretta
Executive Summary
Flexion CEO Mike Clayman shares expectations for Zilretta for knee osteoarthritis and discusses plans for commercialization in an interview at the Biotech Showcase in January.
You may also be interested in...
Flexion's Zilretta Poised For Market Of Diabetics With Knee Pain
FDA labeling in knee pain osteoarthritis is favorable for long-acting steroid Zilretta and a sales force is lined up, but Flexion has its commercial work cut out competing with very cheap generics.
Finance Watch: OncoMed Cuts Costs To Conserve Capital While Public, Private Peers Raise Cash
OncoMed lays off half its employees after a series of recent clinical setbacks. Meanwhile, six public companies raise $1.64bn in $100m-plus follow-on and debt offerings, SV Health Investors closed a $400m venture capital fund and eight therapeutics firms grabbed $247.5m in VC cash.
Flexion's OA Knee Injection On Track For H2 Filing
Burlington, Mass.-based Flexion Therapeutics Inc.'s long-acting steroid injection Zilretta has been associated with statistically significant improvements in pain relief in a pivotal Phase III study in patients with knee osteoarthritis, countering disappointing results from a Phase IIb study reported last year and keeping the product in line for a US NDA submission in the second half on 2016.